Skip to main content
Boyu Hu
( out of 352 reviews )

Boyu Hu, MD

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

2D, Hematology
2000 Circle of Hope
Salt Lake City , UT 84112

Dr. Boyu Hu is an Associate Professor of Medicine and the Director of Lymphoma and Chronic Lymphocytic Leukemia (CLL) within the Division of Hematology and Hematologic Malignancies at the Huntsman Cancer Institute/University of Utah. He is a clinical research scientist who specializes in lymphoid malignancies (i.e. non-Hodgkin lymphoma and Hodgkin lymphoma) and CLL who has been the principal investigator on over 25 phase I, II and III clinical trials investigating novel treatments and combination therapies for patients diagnosed with lymphoma and CLL. His contributions to the field have led to the direct FDA approval and development of targeted therapies, bispecific antibodies, and chimeric antigen receptor T-cell therapies. Nationally, he serves as a member and the Huntsman Cancer Institute representative for the National Comprehensive Cancer Network B-cell Lymphoma Guidelines committee. He is a NIH/NCI funded investigator through his work within the National Clinical Trial Network (NCTN), including being a member within the SWOG Lymphoma and Adolescent and Young Adult committees and The Children’s Oncology Group Hodgkin Lymphoma committee. Through the NCTN, he is currently the co-chair and co-national principal investigator for AHOD2131 (NCT05675410), a randomized phase III clinical trial investigating the incorporation of novel immuno-oncology agents for the treatment of early stage Hodgkin lymphoma, and the chair and national principal investigator for S2506 MOZART MZL (NCT07638722), a randomized phase II clinical trial investigating bispecific therapy alone and in combination with zanubrutinib or polatuzumab vedotin for the treatment of relapsed/refractory marginal zone lymphoma.

To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through MyChart.

For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

Board Certification

American Board of Internal Medicine
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)

Patient Rating

Patients consistently describe Dr. Hu as highly knowledgeable and thorough, with a clear ability to explain diagnoses and treatment options in understandable terms. Commenters emphasize his empathy, attentiveness, and willingness to listen, saying he treats them with respect and supports them through difficult care decisions. Many note strong trust in his recommendations, appreciation for his collaborative approach with other clinicians, and willingness to recommend him to others.

Generated via Patient Reviews

5.0 /5
( out of 352 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.


May 22, 2026
HUNTSMAN CANCER INSTITUTE

Dr Hu is very thorough and he collaborates with other doctors to ensure I get total care.

Apr 30, 2026
HUNTSMAN CANCER INSTITUTE

Dr. Hu is the best! He has successfully treated me into remission for 3 years and now, after relapse, will treat me again with a plan to permanently cure. Thanks again Dr. Hu! Trey

Apr 22, 2026
HUNTSMAN CANCER INSTITUTE

He is the finest doctor that I or any patient could hope to have.

Feb 28, 2026
HUNTSMAN CANCER INSTITUTE

The biggest thing that touched me about Dr. Hu was that he was more hurt and was more bothered than I was when I failed my first round of chemo. That is empathy.

Feb 27, 2026
HUNTSMAN CANCER INSTITUTE

Great doctor, took the time to listen to our concerns and then addressed them in a way we could understand.

Feb 26, 2026
HUNTSMAN CANCER INSTITUTE

Dr. Hu is great. He's extremely knowledgeable and does a great job making sure that I understand what's going on as well as next steps. Although I hope people do not need his expertise, I would highly recommend him to anyone that does.

Feb 21, 2026
HUNTSMAN CANCER INSTITUTE

He is the best of the best

Feb 20, 2026
HUNTSMAN CANCER INSTITUTE

Dr Hu listens and helps you understand your journey, along with allowing for your imput and listening to your concerns for the best treatment options.

Feb 06, 2026
HUNTSMAN CANCER INSTITUTE

Dr. Hu is the best. He is super knowledgeable, kind, and focused on finding the best treatment for you.

Feb 06, 2026
HUNTSMAN CANCER INSTITUTE

He listens to me, asks questions to clear the problem and explains everything about the treatment schedule. A big thanks to Dr. Hu.

Jan 21, 2026
HUNTSMAN CANCER INSTITUTE

All you could ask for in a medical professional.

Jan 16, 2026
HUNTSMAN CANCER INSTITUTE

Dr. Hu has been helping me during this difficult time, answering my questions and giving words of encouragement.

Jan 15, 2026
HUNTSMAN CANCER INSTITUTE

Dr. Hu has always treated me with respect and listened to my questions and answered them so I could understand the answer

Jan 02, 2026
HUNTSMAN CANCER INSTITUTE

He Was Very Kind And Friendly And Knew What He Was Telling Us .

Dec 19, 2025
HUNTSMAN CANCER INSTITUTE

He is so personable and caring about you.

Nov 20, 2025
HUNTSMAN CANCER INSTITUTE

I liked Him Very Much .

Nov 20, 2025
HUNTSMAN CANCER INSTITUTE

He is generous with his time. He is gracious. He listens. He is open to medical questions outside his specialty. He explains complicated issues in layman's terms. He is respectful of me. I feel that he is in my ¿corner¿. He is wise beyond his years.

Oct 07, 2025
HUNTSMAN CANCER INSTITUTE

An excellent doctor.

Oct 03, 2025
HUNTSMAN CANCER INSTITUTE

Very nice dr hu and knowledgeable

Sep 29, 2025
HUNTSMAN CANCER INSTITUTE

The doctor was extremely knowledgeable about my condition. I has seen many doctors, but by far the most excellent and experienced doctor I have ever seen.

Jul 15, 2025
HUNTSMAN CANCER INSTITUTE

Great individual, always willing to answer our questions with care and attention.

Jul 07, 2025
HUNTSMAN CANCER INSTITUTE

Very knowledgeable and helpful.

May 29, 2025
HUNTSMAN CANCER INSTITUTE

He is very concerned about presenting all treatment options and insuring that the patient is fully informed.

May 11, 2025
HUNTSMAN CANCER INSTITUTE

A completely dedicated professional

May 10, 2025
HUNTSMAN CANCER INSTITUTE

Dr. Hu is a very caring doctor and listens well.

May 08, 2025
HUNTSMAN CANCER INSTITUTE

Dr. Hu always listens to my concerns and answers them in a way I understand what happening. I recommend him Hartley

May 02, 2025
HUNTSMAN CANCER INSTITUTE

Excellent knowledge regarding lymphoma. Provides excellent care. I trust him completely! My therapy has provided me with extended wonderful quality of life. I couldn't be more pleased. Thanks to Dr Hu and his wonderful team.

Apr 18, 2025
HUNTSMAN CANCER INSTITUTE

Dr Hu is a wonderful doctor and was attentive and caring. I will forever be grateful for his guidance thru my Lymphoma. I appreciate especially the UofU setting up appointments when needed. I would recommend him to everyone.

Mar 27, 2025
HUNTSMAN CANCER INSTITUTE

Dr. Hu is efficent, courteous and attentive.

Feb 14, 2025
HUNTSMAN CANCER INSTITUTE

Dr. Hu was kind, thorough, and explained my diagnosis including his care recommendations along with the reasoning behind them.

Jan 24, 2025
HUNTSMAN CANCER INSTITUTE

Genius [TRANSLATED]

Nov 21, 2024
HUNTSMAN CANCER INSTITUTE

he is a wonderful caring physician. I would recommend him to anyone who is experiencing a similar situation.


Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor (Clinical)
Academic Divisions Hematology & Hematologic Malignancies
Board Certification
American Board of Internal Medicine
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)

Education history

Fellowship Hematology/Oncology - University of Texas MD Anderson Cancer Center Fellow
Residency Internal Medicine - Hospital of the University of Pennsylvania Resident
Internship Internal Medicine - Hospital of the University of Pennsylvania Intern
Professional Medical Medicine - Case Western Reserve University School of Medicine M.D.
Undergraduate Duke University B.S.

Selected Publications

Journal Article

  1. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Altahan A, Andreadis B, Bartlett NL, Budde LE, Caimi PF, DeVos S, Dholaria B, Fayad LE, Gaballa S, Habermann TM, Hernandez-Ilizaliturri F, Hu B, Kamdar M, Karimi Y, Kelsey CR, King R, Kline J, Krivacic S, LaCasce AS, Landsburg D, Lim M, Messmer M, Pophali P, Rabinovitch R, Ramakrishnan P, Reid E, Riedell P, Roberts KB, Saha A, Saito NG, Sawalha Y, Smith SD, Swinnen LJ, Tuscano J, Vose JM, Dwyer M, Sundar H (2026). B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw, 24(9).
  2. Baron K, Hu B (2026). Advanced Stage Hodgkin Lymphoma: A Review on Frontline Treatment Advances. Cancer J, 32(3).
  3. Swomley A, Epperla N, Horns J, Das R, Hu B, Ermann D (2026). CLO26-125: Treatment Intensity of Dose-Adjusted EPOCH-R and Its Relationship to Outcomes in Aggressive B-Cell Non-Hodgkin Lymphoma. J Natl Compr Canc Netw, 24(3.5).
  4. Ermann D, Vardell V, Zacholski E, Fegley A, Modi D, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Ba Aqeel S, Borogovac A, MacDougall K, Kothari S, Kress A, Travers E, Chilakamarri N, Brem E, Ayyappan S, Sigmund A, Bond D, Fitzgerald L, Wagner C, Hu B, Stephens DM, Shah H (2026). Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk.
  5. Lo AC, Milgrom SA, Vega RM, Hodgson D, Chapman H, Kessel S, Cho SY, Schoder H, Mhlanga J, Pandit-Taskar N, Lai H, Gowdy C, Qi J, Abu-Ata N, Hu B, Seelisch J, Keller F, Castellino SM, LaCasce A, Grover N, Evens A, DuVall A, Allen P, Renfro LA, Wu Y, Kelly KM, Hoppe BS (2025). Enhancing Radiotherapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131. Int J Radiat Oncol Biol Phys, 125(3), 737-742.
  6. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Karimi Y, Kelsey CR, King R, Kline J, Krivacic S, LaCasce AS, Landsburg D, Lim M, Messmer M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Saito NG, Smith SD, Swinnen LJ, Tuscano J, Vose JM, Dwyer M, Sundar H (2025). NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025. J Natl Compr Canc Netw, 23(10).
  7. Brooks TR, Zabor EC, Bedelu Y, Yang X MD, Karimi YH, Nedved AN, Wang Y, Dave NK, Landsburg DJ, Baron K, Hu B, Trotier D, Pophali PA, Miller J PharmD, Grover NS, Reinert C, Major A, Schwarz T, Patel K, Salafian K MD, Ayers EC, Sundaram S, Brody JD, McKenna M, Tiger YKR, Sears-Smith M, Ghosh N, Peterson C DO, Khan C, Bliven SP MD, Narkhede M, Gibson A, Kline J, Munoz J, Garza Morales R, Ho C, Smith SD, Niu A MD, Hernandez-Ilizaliturri FJ, Chinyengetere F MDPhD, Dave SS, Abdel-Razeq N, Alhaj Moustafa M, Caimi P, Hill BT (2025). Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood.
  8. Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, Ermann DA, Fitzgerald LA, Hu B, Shah HR (2025). Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens. Clin Lymphoma Myeloma Leuk.
  9. Pierce AL, Okcu I, Nowakowski G, Tolu S, Amengual J, Ross C, Graber J, Bock A, Hu B, Ermann D (2025). HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era. J Natl Compr Canc Netw, 23(3.5).
  10. Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, Hu B, Beitinjaneh A, Weng WK, Kim YH, Khodadoust MS, Huen AO, Williams LM, Ma A, Huang E, Ganpule A, Nagar SD, Sripakdeevong P, Cullingford EL, Karnik S, Dequeant ML, Patel JN, He XS, Li Z, He QA, Mendonez JH, Keegan A, Horwitz SM (2024). Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol.
  11. Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC (2024). Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers. Haematologica, 110(3).
  12. Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach A, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW (2024). Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med, 391(15), 1379-1389.
  13. Azim A, Hu B, Gilligan S, Sarwal A, Hartsell S, Pandya V, Raphael KL (2023). How I Evaluate a High Anion Gap Metabolic Acidosis. Clin J Am Soc Nephrol, 19(4), 525-527.
  14. Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J (2023). Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv, 7(21), 6630-6638.
  15. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica, 108(11), 3025-3032.
  16. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H (2023). NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw, 21(11), 1118-1131.
  17. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk, 24(2), 94-104.e6.
  18. Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Hodgson D, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum K, Perry AM, Kovach A, Constine LS, Shields LK, Prica A, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW (2023). 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol, 41 Suppl 2, 33-35.
  19. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. Am J Hematol, 98(7), E172-E174.
  20. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leukemia & Lymphoma, 64(2), 356-363.
  21. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2022). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med, 12(3), 2624-2636.
  22. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA (2021). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clin Cancer Res, 28(15), 3242-3247.
  23. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol, 7(6), 101035.
  24. Dave H, Terpilowski M, Mai M, Toner K, Grant M, Stanovich M, Lazarski C, Shibli A, Maglo P, Hog F, Schore R, Glenn M, Hu B, Hanley P, Ambinder R, Bollard CM (2021). Tumor associated antigen specific T cells with nivolumab are safe and persist in vivo in rel/ref Hodgkin Lymphoma. Blood Adv, 6, 473-485.
  25. Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp NJ (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. J Transl Genet Genom, 5, 189-199.
  26. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kangal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson, P, Burger J, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG (2019). Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol, 185(5), 852-864.
  27. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kangal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson, P, Burger J, Jain N, Ferrajoli A, Bose P, Estov Z, Keating M, Wierda WG (2019). Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol, 187(3), 307-318.
  28. Hu B, Takahashi K, et al (2018). Clinical Implications of Cancer Gene Mutations in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide. Blood, 131(16), 1820-32.
  29. Hu Z, Hu B, Collins JF (2007). Prediction of synergistic transcription factors by function conservation. Genome Biol, 8(12), R257.

Review

  1. Hu B, Oki Y (2018). Novel Immunotherapy Options for Extranodal NK/T-cell Lymphoma. [Review]. Front Oncol, 8(139).

Case Report

  1. Gociman S, Baron K, Hu B, Zussman J, Madigan LM (2022). Blistering Lesions Associated With Loncastuximab Tesirine. JAMA Dermatol, 158(7), 831-832.
  2. Hu B, Patel JL, Tao R, Cannon RB, Monroe M, Goyal G (2022). Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation. J Natl Compr Canc Netw, 20(6), 1-4.

Letter

  1. Bock AM, Hao P, Xu Y, Luttwak E, Thiruvengadam SK, Sekaran K, Sano D, Vaughn J, Sharp J, Major A, Patel V, Smilnak G, Araujo N, Mynam R, Reef D, Palmeri M, Gerber D, Abhyankar A, Baek G, Falade A, Iqbal M, Hu B, Geethakumari PR, Durani U, Di M, Niu A, Cherng HJ, Rhodes JM, Grover N, Pophali P, Feldman T, Shanmugasundaram K, Svoboda J, Voorhees T, Diefenbach C, Karimi Y, Karmali R, Herrera AF, Torka P, Epperla N (2026). Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers. [Letter to the editor]. Hemasphere, 10(4), e70346.
  2. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. [Letter to the editor]. Am J Hematol, 99(3), 494-496.
  3. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174.